LH
$270.62
Labcorp Holdings Inc.
Intraday
Recent News
Q4 Earnings Outperformers: Labcorp (NYSE:LH) And The Rest Of The Testing & Diagnostics Services Stocks
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how testing & diagnostics services stocks fared in Q4, starting with Labcorp (NYSE:LH).
Is This the Right Time to Hold Labcorp Stock in Your Portfolio?
LH eyes growth via specialty test expansion, acquisitions and LaunchPad savings, but currency headwinds and macro pressures cloud the outlook.
A Look At Labcorp (LH) Valuation After Recent Share Price Strength
Labcorp Holdings (LH) continues to attract attention after recent share price moves, with the stock last closing at $289.12. Investors are weighing this level against the company’s fundamentals in diagnostics and biopharma laboratory services. See our latest analysis for Labcorp Holdings. That recent move to $289.12 sits within a solid run, with a 30-day share price return of 6.48% and a year-to-date share price return of 14.89%. The 3-year total shareholder return of 47.25% points to a...
Is It Time To Reconsider Labcorp (LH) After Strong Healthcare Sector Coverage And DCF Upside?
If you are wondering whether Labcorp Holdings is priced attractively right now, starting with a clear look at its valuation can help you decide how it fits into your portfolio. The stock recently closed at US$289.12, with reported returns of 2.3% over 7 days, 6.5% over 30 days, 14.9% year to date, 16.4% over 1 year, 45.9% over 3 years, and 48.5% over 5 years. Recent news coverage has focused on Labcorp Holdings' position in the healthcare sector and how its testing and diagnostics...
Did Labcorp’s 2026 Revenue Outlook and Buybacks Just Reframe Labcorp Holdings' (LH) Investment Narrative?
In February 2026, Labcorp Holdings Inc. reported past fourth-quarter 2025 sales of US$3,515.8 million and net income of US$164.7 million, alongside full-year 2025 sales of US$13.95 billion and net income of US$876.5 million, while also completing a US$3.64 billion share repurchase program initiated in 2021. The company’s 2026 revenue guidance of US$14.61 billion to US$14.79 billion, supported by new specialty tests and biopharma-focused investments, highlights how its capital deployment and...